Washington is running two China strategies at once, and this is the week they collide. Operation TrialBlazer is the carrot—an HHS initiative to win clinical trials back to the United States by cutting six to twelve months off early development timelines. The House Select Committee probe is the stick—with five pharma CEOs due to respond by Friday. Carrot and stick, aimed at the same problem, from two different arms of the same government.
The numbers behind TrialBlazer are sobering. China now registers more clinical trials than the United States. It surpassed the U.S. in early phase studies. American companies spent more than $137 billion licensing Chinese assets, which HHS notes means U.S. investment is helping Chinese firms build intellectual property, generate first in human data, and establish clinical track records outside the United States. If trends hold, HHS projects drugs from Chinese biotechs could account for 35% of FDA approvals by 2040.
TrialBlazer’s answer is speed. The industry’s answer is also speed—but it is the speed of doing deals with Chinese partners rather than waiting for Washington to fix the U.S. system. AstraZeneca has signed four China licensing deals since the start of 2025, two of them last week alone, trailing only Roche. The market has already spoken. Friday is when Washington gets its formal response, but the industry answered with its checkbook months ago.
Operation TrialBlazer: The Right Diagnosis, the Incomplete Prescription
What Happened: HHS launched Operation TrialBlazer on June 22 to reverse the migration of clinical research to China. Acting FDA Commissioner Kyle Diamantas said the overseas migration undermines both patient access and American standing in biomedical innovation. The comment window on the related Expedited IND pilot closes July 22.
What TrialBlazer Actually Proposes
The initiative focuses on the regulatory portion of the early trial timeline. The specific interventions: pair sponsors with academic medical centers and CROs to prepare first in human applications, clarify IND requirements so companies know exactly what the FDA expects before they file, reform IRB processes to reduce the time from application to ethics approval, and cut six to twelve months off the path from candidate selection to first patient dosed.
These are real improvements. A clearer IND process reduces wasted time on applications that get rejected for avoidable reasons. Faster IRB review speeds the ethics approval that every trial requires before a single patient can be enrolled. Pairing sponsors with experienced academic centers and CROs gives smaller biotechs access to operational expertise they may lack internally. None of this is trivial.
Why It Probably Is Not Enough
The honest assessment is that TrialBlazer addresses the part of the timeline the FDA controls, and the FDA is not the binding constraint. The bottlenecks that actually determine how fast a trial gets to first patient are operational, not regulatory. Site activation—the process of negotiating contracts with hospitals, setting up the physical infrastructure for a trial, training site personnel, and securing the supply chain for the investigational drug—takes months in the United States. IRB review, which TrialBlazer gestures at reforming, involves a patchwork of institutional review boards at each participating site, many with different requirements, different timelines, and different interpretations of the same regulations. And patient recruitment—finding eligible patients, consenting them, and enrolling them into the trial—is the single largest driver of trial cost and timeline in most therapeutic areas.
China’s advantage is not just faster paperwork at the regulatory level. It is faster everything, at lower cost, with a larger and in many cases more treatment naive patient population. Chinese hospitals can activate sites in weeks rather than months. The centralized trial approval system eliminates the patchwork of institutional variation. And the sheer size of the patient population means enrollment happens faster, often dramatically faster, than in the United States or Europe.
Six to twelve months of saved IND time is meaningful. But if the operational bottlenecks remain—and TrialBlazer does not have the authority to force standardized site contracts, overhaul the IRB system at the institutional level, or change the economics of patient recruitment—the gap between U.S. and Chinese trial speed narrows at the margin rather than closing. BioPharma Dive framed the question directly: U.S. trials keep losing ground to China, and it is not clear TrialBlazer is enough to catch up.
The Broader Context: Carrot and Stick, Same Week
TrialBlazer is the carrot. Friday’s deadline is the stick. Both are aimed at the same problem: American pharmaceutical innovation is increasingly dependent on Chinese clinical infrastructure, and Washington considers that a national security vulnerability.
The carrot says: we will make the United States faster and easier, so companies choose to stay. The stick says: if you did not stay, explain yourself. The tension between the two approaches is itself revealing. If TrialBlazer were sufficient, the stick would be unnecessary. If the stick were sufficient, the carrot would be redundant. Running both simultaneously suggests Washington is not confident that either alone will change the industry’s behavior. And given that AstraZeneca signed two China deals last week while both the carrot and the stick were on display, that lack of confidence appears justified.
Our Pro brief analyzes what actually determines speed to first patient and whether TrialBlazer addresses the binding constraints. [Details below.]
AstraZeneca Is Now the Second Most Active China Dealmaker in Pharma
What Happened: AstraZeneca has signed four licensing deals with Chinese drugmakers since the start of 2025, trailing only Roche among major pharmaceutical companies, according to BioPharma Dive. Two of those deals came last week.
What AstraZeneca’s Behavior Tells You
Everyone in pharma will say the right things about the congressional probe this week. Carefully worded statements about commitment to ethical research, data protection, and patient safety. If you want to know what the industry actually believes, watch what companies do rather than what they say.
AstraZeneca signed a kidney disease siRNA collaboration with CSPC worth up to $1.77 billion on Monday. On Friday it licensed an inhaled respiratory drug from Sino Biopharmaceutical. Two deals in one week, in the same seven day stretch that the House Select Committee’s letters to five of its peers were making headlines. That is not a company that expects meaningful legislative restrictions on China licensing.
AstraZeneca is not among the five named in the probe—Merck, AbbVie, Lilly, Pfizer, and BMS are. That distinction gives it more operational freedom. But its behavior reveals the underlying calculation that the entire industry is making: the political risk is real but manageable, the science is too good to abandon, and the first movers who keep building China pipelines will be better positioned than the ones who pause.
The four AstraZeneca deals since 2025 join a broader landscape we have tracked since January. BMS/Hengrui ($15.2 billion). Pfizer/Innovent ($10.5 billion). Lilly/Haisco ($3 billion plus). Lilly/Abbisko (undisclosed). GSK/SiranBio ($1 billion). Merck/Kelun Biotech (sac TMT). BioNTech/DualityBio ($1 billion). K2/Antengene ($2 billion). AstraZeneca/CSPC (three deals). The total China licensing pipeline exceeds $50 billion in 2026 alone. No congressional inquiry is going to reverse a flow of that magnitude. The question is whether it adds enough friction to slow the pace at the margin.
China Medical System Taps Insilico for CNS
What Happened: China Medical System Holdings signed a 1.2 billion yuan collaboration with Insilico Medicine targeting a mass market CNS indication, according to Fierce Biotech.
Why This Matters: The deal illustrates that the licensing flow runs both ways. Western pharma has been buying Chinese clinical assets all year. Now Chinese pharma is buying Western AI drug discovery capability. Insilico, the AI discovery platform, has partnerships with Takeda (just signed), SK Biopharmaceuticals ($2.5 billion), Servier ($888 million), and Sanofi. A Chinese pharmaceutical company reaching for AI powered drug discovery reflects the same competitive logic driving the entire industry: AI tools that accelerate candidate identification and molecular design are valuable regardless of which side of the Pacific the buyer sits on.
The CNS focus is notable because it is one of the hardest therapeutic areas for traditional drug development—high failure rates, complex endpoints, long trials. If AI can genuinely accelerate target identification and candidate optimization in CNS (a thesis that Insilico’s $2.5 billion SK deal also targets), the impact would be disproportionate in a field where traditional approaches have failed more often than they have succeeded.
Two Thirds of Venture Money Went to Companies Already in the Clinic
What Happened: About two thirds of venture rounds in the first half went to startups with a drug already in human testing, according to BioPharma Dive.
The Barbell Gets More Extreme
This confirms and sharpens the financing barbell we flagged last week. Capital is flowing freely to de risked, clinical stage companies. Early stage and preclinical companies are being starved. The numbers are stark: nearly 60% of venture rounds topped $100 million, those large deals were worth $7.5 billion (up 23% year over year), but that capital is concentrating in companies that have already demonstrated clinical proof of concept.
The logic is rational for each investor. A clinical stage company with human data, a defined regulatory path, and potential M&A interest from large pharma is a lower risk bet than a preclinical company with a promising but unvalidated hypothesis. In an environment where the M&A market is rewarding de risked assets with premiums of 40% to 100% (Apogee at 49%, Crinetics at 99%), the incentive to invest at the clinical stage rather than the preclinical stage is overwhelming.
The problem is what this means five to ten years from now. The Phase 3 assets that large pharma paid $10 billion to acquire this year—Crinetics, Apogee, Nuvalent—were preclinical companies a decade ago, funded by investors willing to take early stage risk. If that willingness continues to decline, the pipeline of acquirable assets in the early 2030s thins out. The patent cliff does not go away. Pharma’s need to acquire does not diminish. But the supply of de risked targets available for acquisition shrinks.
The irony is that the current M&A boom, which depends on a healthy supply of clinical stage assets, is itself being funded by investors who are refusing to create the next generation of those assets. The system works today because it is spending down the inventory of companies that were funded in earlier, more generous venture cycles. When that inventory runs low, the M&A market has a supply problem.
FDA Moves on Hub and Spoke Manufacturing Registration
What Happened: The FDA proposed a streamlined pathway for registering hub and spoke production facilities and clarified how foreign API producers should register.
Why This Matters: Hub and spoke manufacturing models, where a central facility coordinates with distributed production sites, have become more common as companies build regional supply chains in response to tariffs (Section 232 effective July 31), geopolitical risk (Iran war commodity disruptions, Strait of Hormuz closure), and the broader onshoring push.
The foreign API registration piece matters more than it sounds. API supply concentration overseas, particularly in China and India, has been the quiet vulnerability under every drug shortage story we have covered this year. The cisplatin and carboplatin shortage in India. The API rerouting due to the Strait of Hormuz closure. The Evonik 15% price increase. The HLB/Hengrui liver cancer rejection over Chinese manufacturing facility issues. Each of these stories traces back to the same root: the world does not have clear visibility into who actually makes the raw materials that go into its medicines.
Clearer registration rules are a small step toward that visibility. They do not solve the concentration problem. But they create a regulatory foundation that lets the FDA, and the industry, better map the supply chain and identify vulnerabilities before they become shortages.
Strategic Themes
1. TrialBlazer Is the Right Idea Aimed at the Wrong Bottleneck
The initiative addresses the regulatory timeline, which is the part of the system the FDA controls. It does not address the operational timeline—site activation, IRB patchwork, patient recruitment—which is where the actual time goes. China’s advantage is not just faster IND review. It is a system built from the ground up for speed at every stage. Narrowing the gap requires reforms that go well beyond what TrialBlazer proposes, and many of those reforms involve institutions (hospitals, academic centers, IRBs) that the FDA does not have authority over.
2. The Industry’s Revealed Preference Is to Keep Dealing with China
Four AstraZeneca deals since 2025. Two last week. BioNTech committing $1 billion to DualityBio. Kailera reading out positive Phase 3 from Hengrui licensed assets. The Hansoh/GSK ADC hitting its OS endpoint. China Medical System buying Insilico’s AI platform. The deal flow has not paused. It has not slowed visibly. Companies are treating the political friction as a cost of doing business rather than a reason to change strategy. Whether that changes depends on Friday’s responses, the committee’s reaction, and whether the Biotech Investment National Security Act gains legislative momentum. Our base case: the friction rises, the deals continue.
3. The Venture Barbell Is a Ticking Clock for the M&A Market
Two thirds of venture money going to clinical stage companies is great for those companies and dangerous for the ecosystem. The M&A boom depends on a supply of de risked assets. Those assets were preclinical companies a decade ago. If preclinical funding stays depressed, the supply of targets available for acquisition in the early 2030s shrinks. The bill for today’s early stage risk aversion comes due later, and the companies that manage to raise and advance through the drought will find themselves in a seller’s market.
4. The FDA’s Manufacturing Registration Move Is Small but Points in the Right Direction
Every drug shortage story this year traces back to overseas API concentration. Cisplatin, carboplatin, the Strait of Hormuz disruption, the HLB/Hengrui rejection over manufacturing issues. Clearer registration rules for hub and spoke facilities and foreign API producers give the FDA better visibility into the supply chain. It does not solve the concentration problem, but it creates the foundation for identifying vulnerabilities before they become crises.
Frequently Asked Questions
What is Operation TrialBlazer?
An HHS initiative launched June 22 to bring clinical trials back to the U.S. by cutting six to twelve months off early development timelines. It pairs sponsors with academic centers and CROs, clarifies IND requirements, and aims to reform IRB processes. The initiative responds to China surpassing the U.S. in clinical trial registrations.
Is TrialBlazer enough to compete with China?
Probably not on its own. It addresses the regulatory timeline the FDA controls, but the operational bottlenecks that determine trial speed—site activation, IRB patchwork, patient recruitment costs—sit outside the FDA’s authority. China’s advantage is system wide speed at lower cost, not just faster regulatory review.
How many China deals has AstraZeneca signed?
Four since the start of 2025, making it the second most active China dealmaker behind Roche. Two came last week alone, while the House China probe was making headlines. AstraZeneca is not among the five named companies in the probe.
What is the venture funding barbell?
About two thirds of first half venture rounds went to companies with a drug already in human testing. Nearly 60% topped $100 million. Capital is concentrating at the clinical stage while preclinical and early stage companies are being starved. The long term risk is a thinning pipeline of acquirable assets.
What is the FDA manufacturing move?
A proposed streamlined registration pathway for hub and spoke production facilities and clarified registration for foreign API producers. Responds to the overseas API concentration that underlies most drug shortage stories this year.
When is the China probe deadline?
Friday, July 17. Three days from today. Merck, AbbVie, Lilly, Pfizer, and BMS must submit their responses to the House Select Committee on China.
BioMed Nexus Pro — What Institutional Subscribers Are Reading Today
TrialBlazer Is Aimed at the Wrong Bottleneck. We detail what actually determines speed to first patient (site activation, IRB review, recruitment), why six to twelve months of IND time will not close the gap with China, and what reforms would genuinely make the U.S. competitive.
Read AstraZeneca’s Behavior, Not Its Statements. We analyze what four China deals since 2025 tells you about how the industry reads Friday’s deadline, what we expect the five named companies to say, and what would actually surprise us.
When the Early Stage Drought Starts to Hurt. We model when the current preclinical funding gap begins to affect the supply of acquirable assets, assess the timing problem for pharma’s M&A pipeline, and identify why founders who raise through the drought will be holding premium assets.
Plus: China Medical System/Insilico AI deal, FDA manufacturing registration analysis, Section 232 tariff countdown (17 days), Revolution filing watch, and the full H2 catalyst calendar.
About BioMed Nexus
BioMed Nexus delivers institutional grade intelligence to biotech and pharma executives, investors, and clinicians. Our daily briefings and deep dive analyses cut through the noise to deliver the strategic insights that drive better decision making in the life sciences.
Subscribe to receive daily updates and gain access to BioMed Nexus Pro institutional intelligence briefs.
